Beung Chul Ahn

List of Publications by Year
in descending order

25 papers	1,697 citations	643344 15 h-index	651938 25 g-index
25 all docs	25 docs citations	25 times ranked	3306 citing authors

#	Article	IF	Citations
1	Predicting treatment outcomes using ^{18}F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110687.	1.4	7
2	Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity. Frontiers in Oncology, 2022, 12, 821391.	1.3	6
3	SKIâ€Gâ€801, an AXL kinase inhibitor, blocks metastasis through inducing antiâ€tumor immune responses and potentiates antiâ€PDâ€1 therapy in mouse cancer models. Clinical and Translational Immunology, 2022, 11, e1364.	1.7	6
4	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2021, 74, 350-359.	1.8	122
5	Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer. European Journal of Cancer, 2021, 143, 113-126.	1.3	30
6	Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2741-2750.	1.2	4
7	Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Cancers, 2021, 13, 3096.	1.7	7
8	Prognostic implications of PD-L1 expression in patients with angiosarcoma. Future Science OA, 2021, 7, FSO691.	0.9	4
9	Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study. Cancers, 2021, 13, 3681.	1.7	3
10	Clinical decision support algorithm based on machine learning to assess the clinical response to antiâ€"programmed death-1 therapy in patients with nonâ€"small-cell lung cancer. European Journal of Cancer, 2021, 153, 179-189.	1.3	16
11	A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Cancer Medicine, 2021, 10, 7012-7020.	1.3	8
12	The Next Target for NSCLC: Let It Be â€œRETâ€. Journal of Thoracic Oncology, 2020, 15, 1803-1805.	0.5	1
13	Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. Immune Network, 2020, 20, e10.	1.6	86
14	Repotrectinib Exhibits Potent Antitumor Activity in Treatment-NaÃ¯ve and Solvent-Frontâ€"Mutant ROS1-Rearranged Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 3287-3295.	3.2	66
15	Real-World Analysis of the Efficacy of Rebiopsy and *EGFR* Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer. Yonsei Medical Journal, 2019, 60, 525.	0.9	23
16	Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1613-1623.	1.2	66
17	Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Annals of Oncology, 2019, 30, 1104-1113.	0.6	205
18	Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma. Scientific Reports, 2019, 9, 19909.	1.6	18

#	ARTICLE	IF	CITATIONS
19	Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma. Cancer Research and Treatment, 2019, 51, 300-312.	1.3	48
20	CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). Journal of Clinical Oncology, 2018, 36, 2702-2709.	0.8	359
21	Characteristics and Outcome of ROS1-Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice. Journal of Thoracic Oncology, 2018, 13, 1373-1382.	0.5	77
22	Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring *ROS1* Rearrangement. Journal of Clinical Oncology, 2017, 35, 2613-2618.	0.8	260
23	Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis. Oncotarget, 2017, 8, 65111-65122.	0.8	23
24	PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Scientific Reports, 2016, 6, 36956.	1.6	196
25	Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck. Clinical Cancer Research, 2015, 21, 544-552.	3.2	56